Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia

CME
30/10/2025 14 min

Listen "Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia "

Descargar episodio Ver en sitio original

Episode Synopsis



Faculty: Christoph U. Correll, MD

Faculty: Jonathan M. Meyer



Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

More episodes of the podcast CME

When Topicals Fail: The New IPC Consensus Every Clinician Should Know 22/12/2025
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40% 18/11/2025
The Fifth Pillar? Closing the Gap in HFrEF 14/11/2025
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer 14/11/2025
MOA: CDH6-Targeted Antibody-Drug Conjugates 14/11/2025
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies 14/11/2025
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates 14/11/2025
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms 14/11/2025
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need 11/11/2025
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment 10/11/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA